With the appearance of targeted therapy and immunotherapy, maintenance has been employed in recurrent/metastatic cervical cancer and achieved longer progression-free survival (PFS) and overall survival (OS) compared with traditional chemotherapy. Previous studies have shown that the addition of maintenance therapy can prolong PFS of patients by 2 to 3 months, and the 2-year OS rate can be increased by about 10%. These latest studies, such as Keynote-826, confirmed the important role of immunotherapy in recurrent/metastatic cervical cancer and other cancers. However, some problems need to be solved in real-world study. Although targeted therapy and immunotherapy could improve survival, the role of maintenance therapy has not been solid in recurrent/metastatic cervical cancer. Furthermore, the influence of immunotherapy on biologic behavior should be explored, (i.e. immunotherapy can cause the change of immune-microcircumstance, immune cells, tumor-infiltrating lymphocytes, PD-L1). More importantly, the accuracy of efficacy prediction determines the treatment indication of immunotherapy, and response evaluation (i.e. how to diagnose pseudoprogression) is also a major issue that deserves our attention. Studies should be designed to firm the role of maintenance therapy in recurrent/metastatic cervical cancer or clarify the effect of immunotherapy on immune-microcircumstance in cancer, or establish more accurate predictive indicators of immunotherapy efficacy, or explore the mechanism and identification method of pseudoprogression.
Studies should be designed to firm the role of maintenance therapy in recurrent/metastatic cervical cancer, or clarify the effect of immunotherapy on immune-microcircumstance in cancer, or establish more accurate predictive indicators of immunotherapy efficacy, or explore the mechanism and identification method of pseudoprogression.
In this research topic, we welcome researchers to submit manuscripts including but not limited to the following topics:
1) The role of maintenance therapy in long-term survival of recurrent/metastatic cervical cancer
2) The role of maintenance therapy in long-term survival of locally advanced cervical cancer
3) Abscopal effect of immune-radiotherapy in metastatic cervical cancer
4) The effect of immunotherapy on immune-microcircumstance in cancer and its mechanism
5) Establish more accurate predictive indicators for immunotherapy
6) Explore the mechanism and identification of pseudoprogression
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
With the appearance of targeted therapy and immunotherapy, maintenance has been employed in recurrent/metastatic cervical cancer and achieved longer progression-free survival (PFS) and overall survival (OS) compared with traditional chemotherapy. Previous studies have shown that the addition of maintenance therapy can prolong PFS of patients by 2 to 3 months, and the 2-year OS rate can be increased by about 10%. These latest studies, such as Keynote-826, confirmed the important role of immunotherapy in recurrent/metastatic cervical cancer and other cancers. However, some problems need to be solved in real-world study. Although targeted therapy and immunotherapy could improve survival, the role of maintenance therapy has not been solid in recurrent/metastatic cervical cancer. Furthermore, the influence of immunotherapy on biologic behavior should be explored, (i.e. immunotherapy can cause the change of immune-microcircumstance, immune cells, tumor-infiltrating lymphocytes, PD-L1). More importantly, the accuracy of efficacy prediction determines the treatment indication of immunotherapy, and response evaluation (i.e. how to diagnose pseudoprogression) is also a major issue that deserves our attention. Studies should be designed to firm the role of maintenance therapy in recurrent/metastatic cervical cancer or clarify the effect of immunotherapy on immune-microcircumstance in cancer, or establish more accurate predictive indicators of immunotherapy efficacy, or explore the mechanism and identification method of pseudoprogression.
Studies should be designed to firm the role of maintenance therapy in recurrent/metastatic cervical cancer, or clarify the effect of immunotherapy on immune-microcircumstance in cancer, or establish more accurate predictive indicators of immunotherapy efficacy, or explore the mechanism and identification method of pseudoprogression.
In this research topic, we welcome researchers to submit manuscripts including but not limited to the following topics:
1) The role of maintenance therapy in long-term survival of recurrent/metastatic cervical cancer
2) The role of maintenance therapy in long-term survival of locally advanced cervical cancer
3) Abscopal effect of immune-radiotherapy in metastatic cervical cancer
4) The effect of immunotherapy on immune-microcircumstance in cancer and its mechanism
5) Establish more accurate predictive indicators for immunotherapy
6) Explore the mechanism and identification of pseudoprogression
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
